English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

"More than 10 years ago, two pivotal trials, the Ontario Clinical Oncology Group trialand START B trial, firmly established that hypofractionated radiation therapy (RT) of40–42.5 Gy in 15–16 fractions over 3 weeks after breast conserving surgery ormastectomy results in similar rates of local recurrence and normal tissue effects. Thisled to a new standard for postoperative whole breast and chest wall RT. Further trialsconfirmed these findings and show that hypofractionated RT can also be applied forother indications, including regional nodal RT and for ductal carcinoma in situ (DCIS).More recently, a so-called ultra-fractionation trial demonstrated that 26 Gy in 5fractions over 1 week was non-inferior to 40 Gy, in 15 fractions in 3 weeks for localrecurrence at 6 years and that late effects were similar between fractionationschedules being a treatment option for most patients with early breast cancer. Severalcountries and departments are now adopting hypofractionated schedules as a newstandard for breast, chest wall or partial breast RT. In addition to the improvement inconvenience and reduction in resources required, hypofractionated RT offers importantbenefits with respect to acute and late toxicity that can improve the quality of life ofpatients receiving breast RT."

Hypofractionated Postoperative Radiation Therapy for Breast Cancer – Do We Need More Evidence or Adapted Reimbursement Policies?